Botox 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FKJH3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,301
Award facts
- Contract value 100% obligated
- $3,300.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,300.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of BOTOX 200 Unit Vials. The award, issued on December 16, 2025, is structured as a firm fixed-price delivery order with an ultimate completion date of January 8, 2026, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products to Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V contract, valued at $499,999,999 with a completion date of December 31, 2036, authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, and medical consumables. The company's selection as a regional prime vendor reflects its demonstrated capability to fulfill the specialized pharmaceutical requirements of the federal military medical system, supported by substantial prior contract performance on numerous delivery orders issued by the DLA's Medical Supply Chain division. The contract employs a 30-month base period with three 30-month option periods to support recurring medical supply needs across Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FKJH3?
SPE2DR26FKJH3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FKJH3 worth?
The government has obligated $3,301 on SPE2DR26FKJH3.
Is contract SPE2DR26FKJH3 an order under another contract?
Yes. SPE2DR26FKJH3 is a delivery order under SPE2DR25D9105, an indefinite delivery contract.
Was contract SPE2DR26FKJH3 competed?
The extent of competition for SPE2DR26FKJH3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award